Ocugen, Inc. (OCGN) Q1 2026 Earnings Call

Investor webinar replay

Watch the replay and follow the connected company analysis, news, and investor updates for Ocugen, Inc..

Watch the replay

Replay transcript excerpt

WEBVTT 00:00:00.031 -- 00:00:05.777 For OCU410 and geographic atrophy, we continue to advance toward Phase 3 development, 00:00:05.777 -- 00:00:10.521 following encouraging Phase 2 data, with the program expected to move through Phase 3 00:00:10.521 -- 00:00:14.525 enrollment toward BLA submission by 2028. Taken 00:00:14.525 -- 00:00:19.650 together, these milestones reflect a disciplined, multi-program strategy designed 00:00:19.650 -- 00:00:24.815 to create value through a series of increasingly important clinical and regulatory 00:00:24.815 -- 00:00:30.201 readouts. I'll now turn the call over to Rita to provide an update on our financial 00:00:30.201 -- 00:00:34.308 results for the quarter ended March 31, 2026. 00:00:34.308 -- 00:00:35.350 Rita? 00:00:35.350 -- 00:00:37.453 Thank you, Shankar. Good morning, everyone. 00:00:37.453 -- 00:00:42.522 Total operating expenses for the three months ended March 31, 2026 were 00:00:42.522 -- 00:00:44.522 $19.4 00:00:44.625 -- 00:00:50.155 million and included research and development expenses of $11.3 million 00:00:50.155 -- 00:00:53.947 and general and administrative expenses of $8.1 million. 00:00:53.947 -- 00:00:59.614 compared to total operating expenses for the three months ended March 31, 2025 00:00:59.614 -- 00:01:04.741 of $16 million that included research and development expenses 00:01:04.741 -- 00:01:09.747 of $9.5 million and general and administrative expenses of $6.5 00:01:09.747 -- 00:01:14.834 million. Ocugen reported a $0.06 net loss per common share for 00:01:14.834 -- 00:01:18.500 the three months ended March 31, 2026 00:01:18.500 -- 00:01:23.547 compared to a $0.05 net loss per common share for the three months ended March 00:01:23.547 -- 00:01:25.249 31, 2025. 00:01:25.249 -- 00:01:30.436 The company's...